MCID: BRC012
MIFTS: 66

Brucellosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Brucellosis

MalaCards integrated aliases for Brucellosis:

Name: Brucellosis 12 73 20 58 54 3 44 15 17 70 32
Mediterranean Fever 12 73 15
Gibraltar Fever 12 20
Undulant Fever 12 20
Malta Fever 12 20
Bang's Disease 12
Maltese Fever 12
Cyprus Fever 20
Rock Fever 20

Characteristics:

Orphanet epidemiological data:

58
brucellosis
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Brucellosis

GARD : 20 Brucellosis is a bacterial infection that spreads from animals to people via unpasteurized dairy products or by exposure to contaminated animal products or infected animals. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs. Brucellosis can cause of range of signs and symptoms, some of which may persist or recur. Initial symptoms may include fever, sweats, malaise, anorexia, headache, fatigue, and/or pain in the muscles, joints, and/or back. Symptoms that may persist or recur include fevers, arthritis, swelling of the testicle and scrotum, swelling of the heart ( endocarditis ), neurologic symptoms (in up to 5% of cases), chronic fatigue, depression, and/or swelling of the liver or spleen. People who are in jobs or settings that increase exposure to the bacteria are at increased risk for infection. Antibiotics are used to treat brucellosis. Recovery may take a few weeks to several months, and relapses are common. Death from brucellosis is rare, occurring in no more than 2% of cases.

MalaCards based summary : Brucellosis, also known as mediterranean fever, is related to tularemia and orchitis, and has symptoms including fatigue, fever and back pain. An important gene associated with Brucellosis is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Colchicine and Interleukin 1 Receptor Antagonist Protein have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and kidney, and related phenotypes are hyperhidrosis and splenomegaly

Disease Ontology : 12 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has symptom fever, has symptom sweat, has symptom headache, has symptom back pain, has symptom physical weakness, has symptom joint pain and has symptom fatigue.

CDC : 3 Brucellosis is an infectious disease caused by bacteria. People can get the disease when they are in contact with infected animals or animal products contaminated with the bacteria. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs, among others.

Wikipedia : 73 Brucellosis is a highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked... more...

Related Diseases for Brucellosis

Diseases related to Brucellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1214)
# Related Disease Score Top Affiliating Genes
1 tularemia 31.2 TNF TLR4 SLC11A1 IL17A
2 orchitis 31.1 TNF IL6 IL2 IL10 CRP
3 proliferative glomerulonephritis 31.0 IL6 IL4 IFNG
4 polyarteritis nodosa 31.0 MEFV IL6 CRP
5 bursitis 30.9 TNF IL6 CRP
6 meningoencephalitis 30.9 TNF IL6 IL10 CRP
7 q fever 30.9 TNF TLR4 SLC11A1 IL6 IL4 IL10
8 cryopyrin-associated periodic syndrome 30.8 IL6 IL1RN CRP
9 hyper-igd syndrome 30.8 SAA1 IL1RN CRP
10 ige responsiveness, atopic 30.7 IL4 IL10 IFNG
11 infective endocarditis 30.7 TNF IL6 IL17A CRP
12 spondylitis 30.7 TNF SAA1 IL6 IL17A IL10 IFNG
13 typhoid fever 30.7 TNF TLR4 SLC11A1 IL6 IFNG CRP
14 polyradiculoneuropathy 30.7 IL17A IL10 IFNG
15 disseminated intravascular coagulation 30.6 TNF IL6 IL10 CRP
16 hereditary periodic fever syndrome 30.6 TNF MEFV
17 mouth disease 30.6 TLR4 IL6 IL10 IFNG CRP
18 endocarditis 30.6 TNF IL6 IL17A IL10 IFNG CXCL8
19 epidemic typhus 30.6 TNF IL10 CRP
20 hypersplenism 30.6 TLR4 IL4 IFNG
21 tenosynovitis 30.6 TNF IL6 CRP
22 arthropathy 30.6 TNF IL6 IFNG CRP
23 scleritis 30.6 TNF IL4 IFNG CRP
24 secondary hemophagocytic lymphohistiocytosis 30.5 TNF ADA
25 plague 30.5 TNF TLR4 IL6 IL2 IL10 CD86
26 panniculitis 30.5 TNF IFNG CRP
27 posterior scleritis 30.5 TNF CRP
28 neutropenia 30.5 TNF IL6 IL2 IL1RN IL10 CXCL8
29 giardiasis 30.5 TGFB1 IL17A IL10
30 toxoplasmosis 30.5 TNF TLR4 TGFB1 IL6 IL4 IL10
31 syphilis 30.5 TNF IL6 IL17A IFNG CRP
32 listeriosis 30.5 TNF IL6 IL18 IL10
33 bilirubin metabolic disorder 30.4 TNF IL6 IL2 CRP
34 ileus 30.4 TNF IL6 IL10 CRP
35 pleural empyema 30.4 IL6 CRP ADA
36 pericardial effusion 30.4 IL6 CRP ADA
37 fabry disease 30.4 TNF IL6 IL10 CRP
38 drug reaction with eosinophilia and systemic symptoms 30.4 TNF CRP
39 urinary tract infection 30.4 TLR4 TGFB1 CRP
40 acne 30.4 TNF TGFB1 IL6 IL1RN CXCL8
41 cryoglobulinemia 30.4 TNF IL6 IFNG
42 polyarticular juvenile idiopathic arthritis 30.4 TNF IFNG
43 myelitis 30.4 TNF IL6 IL17A IL10 CXCL8
44 intestinal tuberculosis 30.4 TNF IFNG CRP
45 macrophage activation syndrome 30.3 TNF IL18 CRP
46 juvenile arthritis 30.3 IL6 IL10 CXCL8 CRP
47 crohn's colitis 30.3 TNF IL2 IFNG CXCL8
48 intermediate uveitis 30.3 TNF IL6 IL2 IL10 IFNG
49 pustulosis of palm and sole 30.3 TNF IL1RN IL17A CXCL8 CRP
50 histiocytosis 30.3 TNF IL17A IFNG

Graphical network of the top 20 diseases related to Brucellosis:



Diseases related to Brucellosis

Symptoms & Phenotypes for Brucellosis

Human phenotypes related to Brucellosis:

58 31 (show top 50) (show all 77)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 58 31 frequent (33%) Frequent (79-30%) HP:0000975
2 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
3 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
6 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
7 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
8 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
9 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
10 abnormality of the gastrointestinal tract 58 31 frequent (33%) Frequent (79-30%) HP:0011024
11 elevated c-reactive protein level 58 31 frequent (33%) Frequent (79-30%) HP:0011227
12 leukopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001882
13 elevated erythrocyte sedimentation rate 58 31 frequent (33%) Frequent (79-30%) HP:0003565
14 septic arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0003095
15 increased circulating igg level 58 31 frequent (33%) Frequent (79-30%) HP:0003237
16 nausea 58 31 frequent (33%) Frequent (79-30%) HP:0002018
17 asthenia 58 31 frequent (33%) Frequent (79-30%) HP:0025406
18 abnormality of hepatobiliary system physiology 58 31 frequent (33%) Frequent (79-30%) HP:0025155
19 failure to thrive 58 31 occasional (7.5%) Occasional (29-5%) HP:0001508
20 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
21 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
22 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
23 hypersplenism 58 31 occasional (7.5%) Occasional (29-5%) HP:0001971
24 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
25 purpura 58 31 occasional (7.5%) Occasional (29-5%) HP:0000979
26 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
27 osteomyelitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002754
28 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
29 liver abscess 58 31 occasional (7.5%) Occasional (29-5%) HP:0100523
30 premature birth 58 31 occasional (7.5%) Occasional (29-5%) HP:0001622
31 abnormality of bone marrow cell morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0005561
32 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
33 immunologic hypersensitivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0100326
34 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
35 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
36 small for gestational age 58 31 occasional (7.5%) Occasional (29-5%) HP:0001518
37 orchitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100796
38 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
39 spontaneous abortion 58 31 occasional (7.5%) Occasional (29-5%) HP:0005268
40 bronchitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012387
41 increased circulating igm level 58 31 occasional (7.5%) Occasional (29-5%) HP:0003496
42 glomerulonephritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000099
43 hip osteoarthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0008843
44 rheumatoid factor positive 58 31 occasional (7.5%) Occasional (29-5%) HP:0002923
45 sacroiliac arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012317
46 erythematous papule 58 31 occasional (7.5%) Occasional (29-5%) HP:0030350
47 chills 58 31 occasional (7.5%) Occasional (29-5%) HP:0025143
48 knee osteoarthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0005086
49 abnormality of the peripheral nervous system 58 31 occasional (7.5%) Occasional (29-5%) HP:0410008
50 cutaneous cyst 58 31 occasional (7.5%) Occasional (29-5%) HP:0025245

Symptoms:

12
  • fatigue
  • fever
  • back pain
  • headache
  • joint pain
  • sweat
  • physical weakness

GenomeRNAi Phenotypes related to Brucellosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CXCL8 IL10 IL17A IL18 TGFB1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CXCL8 IL10 IL17A IL18 IL2 TGFB1

MGI Mouse Phenotypes related to Brucellosis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ADA CD86 CRP IFNG IL10 IL17A
2 hematopoietic system MP:0005397 10.37 ADA CD86 IFNG IL10 IL17A IL18
3 cellular MP:0005384 10.36 ADA CD86 IFNG IL10 IL18 IL1RN
4 immune system MP:0005387 10.36 ADA CD86 CRP IFNG IL10 IL17A
5 growth/size/body region MP:0005378 10.32 ADA IFNG IL10 IL17A IL18 IL1RN
6 digestive/alimentary MP:0005381 10.31 ADA IFNG IL10 IL17A IL18 IL2
7 cardiovascular system MP:0005385 10.3 ADA CRP IFNG IL10 IL18 IL1RN
8 endocrine/exocrine gland MP:0005379 10.22 ADA CD86 IFNG IL10 IL17A IL2
9 integument MP:0010771 10.21 IFNG IL10 IL17A IL18 IL1RN IL4
10 mortality/aging MP:0010768 10.21 ADA IFNG IL10 IL17A IL18 IL1RN
11 liver/biliary system MP:0005370 10.1 ADA IFNG IL10 IL2 IL4 IL6
12 muscle MP:0005369 9.97 ADA CD86 IFNG IL10 IL18 IL6
13 reproductive system MP:0005389 9.9 ADA IFNG IL10 IL1RN IL2 IL4
14 neoplasm MP:0002006 9.86 IFNG IL10 IL2 IL6 SLC11A1 TGFB1
15 respiratory system MP:0005388 9.65 ADA IFNG IL10 IL17A IL2 IL4
16 skeleton MP:0005390 9.36 ADA IFNG IL10 IL17A IL1RN IL4

Drugs & Therapeutics for Brucellosis

Drugs for Brucellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Colchicine Approved Phase 2, Phase 3 64-86-8 6167 2833
2 Interleukin 1 Receptor Antagonist Protein Phase 3
3 Pharmaceutical Solutions Phase 3
4 Immunoglobulins Phase 3
5 Antibodies Phase 3
6 Immunoglobulins, Intravenous Phase 3
7 Antirheumatic Agents Phase 2, Phase 3
8 Antimitotic Agents Phase 2, Phase 3
9 Tubulin Modulators Phase 2, Phase 3
10
Rilonacept Approved, Investigational Phase 2 501081-76-1 104924
11
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
12
Ethanol Approved Phase 2 64-17-5 702
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
14
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
15 Kallikreins Phase 2
16 Anti-Inflammatory Agents Phase 2
17 Narcotics Phase 2
18 Narcotic Antagonists Phase 2
19 Analgesics, Opioid Phase 2
20
Isoniazid Approved, Investigational Phase 1 54-85-3 3767
21
Rifampicin Approved Phase 1 13292-46-1 5458213 5381226
22
Kanamycin Approved, Investigational, Vet_approved Phase 1 59-01-8, 8063-07-8 6032
23
Moxifloxacin Approved, Investigational Phase 1 151096-09-2, 354812-41-2 152946
24
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
25
Pyrazinamide Approved, Investigational Phase 1 98-96-4 1046
26
Streptomycin Approved, Vet_approved Phase 1 57-92-1 19649
27
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
28 Antimetabolites Phase 1
29 Catalase Phase 1
30 Fluoroquinolones Phase 1
31 Vitamin B3 Phase 1
32 Antitubercular Agents Phase 1
33 Hypolipidemic Agents Phase 1
34 Nicotinic Acids Phase 1
35 Lipid Regulating Agents Phase 1
36 Norgestimate, ethinyl estradiol drug combination Phase 1
37 Immunologic Factors
38 Immunoglobulin G
39 Immunoglobulin M
40 Anti-Bacterial Agents
41 Antibiotics, Antitubercular
42 Anti-Infective Agents

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial Completed NCT02602028 Phase 4 colchicine
2 A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Completed NCT01705756 Phase 3 Kineret
3 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
4 A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs Completed NCT02059291 Phase 3 Canakinumab;Placebo
5 An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF)) Completed NCT02911857 Phase 3
6 Colchicine in Postoperative Fontan Patients (CPFP) Terminated NCT03575572 Phase 2, Phase 3 Colchicine
7 Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation Unknown status NCT02175589 Phase 2
8 An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever Completed NCT01088880 Phase 2 Canakinumab
9 Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF) Completed NCT00582907 Phase 2 Rilonacept;Placebo
10 A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever Completed NCT01148797 Phase 2 Canakinumab
11 Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study Completed NCT03446209 Phase 2 Tocilizumab Infusion RoAcemtra (EU);0.9% physiological saline
12 Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis Completed NCT00094900 Phase 2 IL-1 Trap
13 Factor XII-associated Cold Autoinflammatory Syndrome (FACAS) Linked to Kallikrein-kinin Pathology: Proof of Concept Treatment With Lanadelumab (DX-2930) Recruiting NCT04278885 Phase 2 Lanadelumab
14 Impact of Colchicine and Low-dose Naltrexone on COVID-19 Disease Progression and Clinical Course in Hospitalized Patients Enrolling by invitation NCT04756128 Phase 2 Colchicine 0.6 mg;Naltrexone
15 Effects of Probiotic Addition to Corticosteroid Treatment for PFAPA Withdrawn NCT02535962 Phase 2
16 Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) Unknown status NCT02775994 Phase 1 Canakinumab
17 An Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMF Completed NCT01075906 Phase 1 colchicine sprinkle capsules;colchicine sprinkle capsules
18 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
19 Assessment of a Functional Test to Detect Familial Mediterranean Fever Unknown status NCT03747315
20 Exertional Muscle Fatigue In FMF Patients Evaluated By MRI And MR Spectroscopy Of The Thigh Unknown status NCT00658060
21 Musculoskeletal Ultrasound of the Ankles in Erysipelas-like Erythema of Familial Mediterranean Fever Unknown status NCT03917277
22 Association Between Basal Proteinuria Levels and Pregnancy Outcomes in Familial Mediterranean Fever Unknown status NCT02092064
23 The Movement Imagery Ability in Patients With Familial Mediterranean Fever Completed NCT04729218
24 Gluten-related Disorders in Patients Affected With Familial Mediterranean Fever Completed NCT03563300
25 Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis Completed NCT04301752
26 Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan Completed NCT01766830
27 An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases Recruiting NCT00001373
28 Real World Study of Classic Infectious Disease Recruiting NCT04020536 Antibiotics
29 Creation of a Tool to Assess Quality of Life in Patient With Auto-inflammatory Diseases Active, not recruiting NCT03569644
30 Heat Intolerance in the Group of FMF Patients Enrolling by invitation NCT01059279
31 Comparison the Effectiveness of Online Aerobic Dance Exercises Versus Physical Activity Counseling in Patients With Juvenile Familial Mediterranean Fever Enrolling by invitation NCT04724993
32 Pain, Sleep, Fatigue, Physical Activity Level, Quality of Life and Exercise Habits in Patients With Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic Enrolling by invitation NCT04403438
33 The Effect of Pilates Based Exercise Practice on Physical and Psychological Parameters in Patients With Behçet and Familial Mediterranean Fever. Enrolling by invitation NCT04402255
34 Characterization of a Functional Test for Mediterranean Family Fever Screening - 2 Not yet recruiting NCT04478409
35 Immunome Project Consortium for Autoinflammatory Disorders Not yet recruiting NCT03919110
36 Investigation of Fever Suspected as a Zoonosis Using Advanced Diagnostic Technologies- a Prospective Cohort Study Not yet recruiting NCT04717622
37 Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency Terminated NCT00260299
38 Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission Withdrawn NCT00323440
39 The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever. Withdrawn NCT02021084

Search NIH Clinical Center for Brucellosis

Cochrane evidence based reviews: brucellosis

Genetic Tests for Brucellosis

Anatomical Context for Brucellosis

MalaCards organs/tissues related to Brucellosis:

40
Liver, Bone, Kidney, Skin, Heart, Bone Marrow, Spleen

Publications for Brucellosis

Articles related to Brucellosis:

(show top 50) (show all 14034)
# Title Authors PMID Year
1
Common Mediterranean fever gene mutations in the Azeri Turkish population of Iran. 54 61
19929404 2010
2
Prevalence and significance of MEFV gene mutations in a cohort of patients with rheumatoid arthritis. 54 61
20031469 2010
3
Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation. 54 61
20008920 2010
4
Familial mediterranean Fever: a retrospective clinical and molecular study in the East of anatolia region of Turkey. 61 54
20177433 2010
5
Expression of the familial Mediterranean fever gene is regulated by nonsense-mediated decay. 61 54
19755381 2009
6
A Japanese case of familial Mediterranean fever with a MEFV gene mutation. 54 61
19998717 2009
7
MEFV mutation carriage in Israeli Jewish individuals from ethnicities with low risk for familial Mediterranean fever. 61 54
19373257 2009
8
Familial Mediterranean Fever: a review for clinical management. 61 54
19091621 2009
9
Increased serum osteoprotegerin levels associated with decreased bone mineral density in familial Mediterranean fever. 61 54
19346738 2009
10
Common MEFV mutations and polymorphisms in an elderly population: an association with E148Q polymorphism and rheumatoid factor levels. 54 61
19473580 2009
11
Clinical features of familial Mediterranean fever: an Italian overview. 61 54
19530512 2009
12
Detection of MEFV gene mutations in patients with inflammatory bowel disease. 61 54
19309279 2009
13
Molecular analysis of MEFV gene mutations among Palestinian patients with Behcet's disease. 54 61
18609258 2008
14
MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 61 54
17566872 2008
15
[Familial Mediterranean fever. Rare manifestation without fever and with inconspicuous family case history]. 61 54
18651363 2008
16
A very frequent mutation and remarkable association of R761H with M694V mutations in Turkish familial Mediterranean fever patients. 61 54
18000697 2008
17
Mutations in the familial Mediterranean fever gene of patients with IgA nephropathy and other forms of glomerulonephritis. 54 61
18177471 2008
18
Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 61 54
18097735 2008
19
Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. 61 54
18035151 2007
20
Unique spectrum of MEFV mutations in Iranian Jewish FMF patients--clinical and demographic significance. 61 54
17938136 2007
21
Cloning, expression and characterization of immunogenic aminopeptidase N from Brucella melitensis. 61 54
17064279 2006
22
Renal amyloidosis in a child with sickle cell anemia. 54 61
16570202 2006
23
The SPRY domain of SSB-2 adopts a novel fold that presents conserved Par-4-binding residues. 54 61
16369487 2006
24
Relationship between HLA-DR, HLA-DQ alleles and MEFV gene mutations in familial Mediterranean fever (FMF) patients. 54 61
16245224 2005
25
[Familial Mediterranean Fever (FMF): from diagnosis to treatment]. 54 61
15745878 2004
26
[Hereditary periodic fever]. 54 61
15243709 2004
27
Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. 54 61
14978665 2004
28
Familial Mediterranean fever with amyloidosis associated with novel exon 2 mutation (S1791) of the MEFV gene. 61 54
14636645 2003
29
Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? 61 54
12966608 2003
30
Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. 54 61
12700594 2003
31
The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. 54 61
12209523 2002
32
Two novel mutations R653H and E230K in the Mediterranean fever gene associated with disease. 61 54
11470495 2001
33
Limited diagnostic usefulness of antibodies to cytoplasmic proteins of Brucella in early-treated human brucellosis. 61 54
11303810 2001
34
The relation between familial Mediterranean fever and amyloidosis. 54 61
10647956 2000
35
The 18-kDa cytoplasmic protein of Brucella species --an antigen useful for diagnosis--is a lumazine synthase. 54 61
10482294 1999
36
Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. 54 61
8852961 1996
37
Pathological changes, distribution and detection of Brucella melitensis in foetuses of experimentally-infected does. 61
33349157 2021
38
Importance of brucellosis control programs of livestock on the improvement of one health. 61
33618618 2021
39
The implications of Rose Bengal test seroconversion in the diagnosis of brucellosis in children in an endemic region. 61
33591841 2021
40
Enthesitis may be one of the signs of severe disease in familial Mediterranean fever. 61
32920724 2021
41
"Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france". 61
33586832 2021
42
Evaluation of the thyroid disorders in children with familial Mediterranean fever. 61
32996072 2021
43
The coexistence of familial Mediterranean fever (FMF) in systemic lupus erythematosus (SLE) patients - A cross sectional study. 61
33794705 2021
44
[Frosted branch angiitis: An uncommon finding in familial Mediterranean fever]. 61
33446349 2021
45
Using urinary neutrophile gelatinase-associated lipocalin for prognosticate renal dysfunction in children with familial Mediterranean fever the study design: a pilot study. 61
33795029 2021
46
COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study. 61
33611656 2021
47
COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review. 61
33611657 2021
48
Characterization of innate immune response to Brucella melitensis infection in goats with permissive or restrictive phenotype for Brucella intramacrophagic growth. 61
33711712 2021
49
The feasibility and acceptability of various bovine brucellosis control strategies in India. 61
33582551 2021
50
Comparative study of IS711 and bcsp31-based polymerase chain reaction (PCR) for the diagnosis of human brucellosis in whole blood and serum samples. 61
33647359 2021

Variations for Brucellosis

Expression for Brucellosis

Search GEO for disease gene expression data for Brucellosis.

Pathways for Brucellosis

Pathways related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR4 TGFB1 SLC11A1 SAA1 MEFV
2
Show member pathways
13.88 TNF TGFB1 IL6 IL4 IL2 IL18
3
Show member pathways
13.81 TNF TLR4 TGFB1 IL6 IL4 IL2
4
Show member pathways
13.67 TNF TGFB1 IL6 IL4 IL2 IL18
5
Show member pathways
13.56 TNF TLR4 TGFB1 IL6 IL4 IL2
6
Show member pathways
13.46 TNF TGFB1 SAA1 IL6 IL4 IL2
7
Show member pathways
13.44 TNF TGFB1 IL6 IL4 IL2 IL18
8
Show member pathways
13.33 TNF TLR4 TGFB1 IL6 IL2 IL18
9
Show member pathways
13 TNF TGFB1 IL6 IL4 IL2 IL17A
10
Show member pathways
12.97 TNF TLR4 IL6 IL2 IL18 IFNG
11 12.94 TGFB1 IL6 IL4 IL2 IFNG CXCL8
12
Show member pathways
12.81 TNF IL4 IL2 IL18 IL10 IFNG
13
Show member pathways
12.8 TNF TLR4 IL6 IL18 CXCL8
14
Show member pathways
12.77 TNF TLR4 TGFB1 IL6 IL2
15
Show member pathways
12.76 TNF TLR4 TGFB1 IL6 IL4 IL2
16
Show member pathways
12.75 TNF IL6 IL2 IL18 IL17A IL10
17 12.73 TNF IL4 IL2 IL1RN IL17A IL10
18
Show member pathways
12.68 TNF TLR4 TGFB1 IL6 IL4 IL2
19
Show member pathways
12.54 TNF TLR4 IL6 IL18 CXCL8
20
Show member pathways
12.53 IL6 IL4 IL2 IL10 IFNG
21
Show member pathways
12.51 TNF IL6 IL4 IL17A IFNG CXCL8
22
Show member pathways
12.51 TNF IL6 IL2 IL18 IL10 CXCL8
23
Show member pathways
12.51 TNF SAA1 IL6 IL4 IL2 IFNG
24 12.45 TNF TLR4 IL18 CXCL8
25
Show member pathways
12.44 TNF TLR4 TGFB1 IL4 IL10 IFNG
26
Show member pathways
12.43 TNF TLR4 IL6 IFNG CXCL8
27 12.41 TNF TLR4 MEFV IL6 IL18 CXCL8
28 12.4 TNF TGFB1 IL6 IL2
29 12.4 TNF TLR4 TGFB1 IL6 IL18 IL10
30
Show member pathways
12.37 TNF IL6 IL1RN IL18 CXCL8
31
Show member pathways
12.35 TNF TLR4 IL6 IL4 IFNG CXCL8
32 12.34 TNF TLR4 TGFB1 IL6 IFNG
33
Show member pathways
12.34 TNF TGFB1 IL6 IL4 IL2 IL18
34
Show member pathways
12.33 TNF TLR4 IL6 CXCL8
35 12.33 TNF IL6 IL1RN IL10 CXCL8
36
Show member pathways
12.28 TNF IL6 IL2 IL10
37 12.22 TNF TLR4 MEFV IL6 IL2 IL18
38 12.18 TNF IL6 IL4 IL2 IL10 IFNG
39 12.14 TNF TLR4 TGFB1 IL6 IL4 IL2
40 12.1 TNF TLR4 TGFB1 IL6 IL10 IFNG
41
Show member pathways
12.09 IL4 IL2 IL18 IFNG
42 12.06 TGFB1 IL6 IFNG CXCL8
43
Show member pathways
12.06 TLR4 TGFB1 IL6 IL17A CXCL8
44 12.06 TLR4 TGFB1 IL2 IL18 CXCL8
45 12.03 TNF TGFB1 IL6 CXCL8
46
Show member pathways
12.03 TLR4 TGFB1 IL6 IL4 IL17A IFNG
47 12.03 TNF TGFB1 SAA1 IL6 IL4 IL18
48 11.99 IL6 IL4 IL2 IFNG CXCL8
49 11.96 TNF IL4 IL2 IL18 IL17A IL10
50 11.94 TNF TLR4 IL6 IL10 CXCL8

GO Terms for Brucellosis

Cellular components related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF TGFB1 SAA1 IL6 IL4 IL2
2 external side of plasma membrane GO:0009897 9.55 TNF TLR4 IL17A CD86 ADA
3 extracellular space GO:0005615 9.44 TNF TGFB1 IL6 IL4 IL2 IL1RN

Biological processes related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.22 TNF TGFB1 IL6 IL4 IL10 CD86
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TNF TLR4 TGFB1 SLC11A1 IL6 IL4
3 positive regulation of cell proliferation GO:0008284 10.18 TGFB1 IL6 IL4 IL2 IFNG CD86
4 positive regulation of protein phosphorylation GO:0001934 10.05 TNF TGFB1 IL2 IFNG
5 positive regulation of protein kinase B signaling GO:0051897 10.04 TNF TGFB1 IL18 CD86
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.03 TNF TLR4 TGFB1 IL6 IL18
7 defense response to Gram-positive bacterium GO:0050830 9.99 TNF IL6 IL17A CRP
8 cellular response to lipopolysaccharide GO:0071222 9.99 TNF TLR4 IL6 IL10 CXCL8 CD86
9 positive regulation of tumor necrosis factor production GO:0032760 9.97 TLR4 IL6 IL17A IFNG
10 positive regulation of inflammatory response GO:0050729 9.97 TNF TLR4 IL2 IL18 IFNG
11 defense response to Gram-negative bacterium GO:0050829 9.96 TLR4 SLC11A1 IL6 IL17A
12 positive regulation of gene expression GO:0010628 9.96 TNF TLR4 TGFB1 SLC11A1 IL6 IL4
13 positive regulation of interleukin-6 production GO:0032755 9.95 TNF TLR4 IL6 IL17A IFNG
14 negative regulation of tumor necrosis factor production GO:0032720 9.94 IL10 IL4 TLR4
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.94 TNF TLR4 IL18 CD86
16 response to glucocorticoid GO:0051384 9.94 TNF IL6 IL1RN IL10
17 regulation of insulin secretion GO:0050796 9.93 TNF IL6 IFNG
18 negative regulation of interleukin-6 production GO:0032715 9.93 TNF TLR4 IL10
19 cellular response to organic cyclic compound GO:0071407 9.93 TNF TGFB1 IL18
20 positive regulation of T cell proliferation GO:0042102 9.93 IL6 IL4 IL2 CD86
21 negative regulation of inflammatory response GO:0050728 9.93 SAA1 MEFV IL4 IL2 IL10 ADA
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.92 TNF IL6 IL18
23 positive regulation of interleukin-8 production GO:0032757 9.92 TNF TLR4 IL6
24 humoral immune response GO:0006959 9.92 TNF IL6 IFNG
25 positive regulation of protein complex assembly GO:0031334 9.91 TNF TGFB1 IFNG
26 negative regulation of fat cell differentiation GO:0045599 9.91 TNF TGFB1 IL6
27 positive regulation of B cell proliferation GO:0030890 9.91 TLR4 IL4 IL2 ADA
28 positive regulation of phagocytosis GO:0050766 9.9 TNF SLC11A1 IFNG
29 T cell activation GO:0042110 9.9 TGFB1 IL4 ADA
30 positive regulation of chemokine production GO:0032722 9.9 TNF TLR4 IL6 IFNG
31 inflammatory response GO:0006954 9.9 TNF TLR4 TGFB1 SLC11A1 MEFV IL6
32 extrinsic apoptotic signaling pathway GO:0097191 9.89 TNF TGFB1 IFNG
33 positive regulation of nitric oxide biosynthetic process GO:0045429 9.89 TNF TLR4 IFNG
34 negative regulation of T cell proliferation GO:0042130 9.89 TGFB1 IL10 CD86
35 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.89 TNF TGFB1 IL10
36 positive regulation of interleukin-12 production GO:0032735 9.89 TLR4 IL17A IFNG
37 acute-phase response GO:0006953 9.89 SAA1 IL6 IL1RN CRP
38 positive regulation of interferon-gamma production GO:0032729 9.89 TNF TLR4 SLC11A1 IL2 IL18
39 positive regulation of interleukin-10 production GO:0032733 9.88 TLR4 IL6 IL4
40 negative regulation of mitotic cell cycle GO:0045930 9.88 TNF TGFB1 IL10
41 lipopolysaccharide-mediated signaling pathway GO:0031663 9.88 TNF TLR4 TGFB1 IL18
42 liver regeneration GO:0097421 9.87 TGFB1 IL6 IL10
43 positive regulation of JAK-STAT cascade GO:0046427 9.87 TNF IL6 IL10
44 microglial cell activation GO:0001774 9.86 TNF IL4 IFNG
45 negative regulation of interleukin-17 production GO:0032700 9.85 TLR4 TGFB1 IFNG
46 negative regulation of myoblast differentiation GO:0045662 9.85 TNF TGFB1 IL18
47 positive regulation of osteoclast differentiation GO:0045672 9.85 TNF IL17A IFNG
48 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.84 TNF TLR4 IL6 IL17A
49 positive regulation of T cell differentiation GO:0045582 9.83 IL4 IL2 ADA
50 positive regulation of immunoglobulin production GO:0002639 9.83 IL6 IL2 IL10

Molecular functions related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF TGFB1 IL6 IL4 IL2 IL1RN
2 growth factor activity GO:0008083 9.35 TGFB1 IL6 IL4 IL2 IL10

Sources for Brucellosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....